Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 8c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $67 million.

GUIDANCE:

Vanda Pharmaceuticals sees Q3 2022 revenue of $240-280 million, versus the consensus of $265.1 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance